Analyst Joseph Stringer of Needham maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to $377.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Joseph Stringer has given his Buy rating due to a combination of factors that emerged from recent engagements with Alnylam Pharma. After meeting with the company at their Cambridge offices, Stringer noted an increased optimism regarding the launch of Amvuttra in the ATTR-CM market. This optimism is reflected in the updated revenue model for Amvuttra, with projections showing a positive trend.
Furthermore, Alnylam reaffirmed its 2025 total product revenue guidance of $2.05-2.25 billion, which bolstered confidence in the company’s growth trajectory. As a result of these insights, Stringer adjusted his price target for Alnylam’s stock from $320 to $377, indicating a strong belief in the company’s future performance and justifying the Buy rating.
In another report released on June 24, BMO Capital also maintained a Buy rating on the stock with a $360.00 price target.
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is neutral on the stock.